JP2006514063A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514063A5
JP2006514063A5 JP2004566119A JP2004566119A JP2006514063A5 JP 2006514063 A5 JP2006514063 A5 JP 2006514063A5 JP 2004566119 A JP2004566119 A JP 2004566119A JP 2004566119 A JP2004566119 A JP 2004566119A JP 2006514063 A5 JP2006514063 A5 JP 2006514063A5
Authority
JP
Japan
Prior art keywords
alkyl
bile acid
reuptake inhibitor
group
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004566119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514063A (ja
Filing date
Publication date
Priority claimed from FR0215722A external-priority patent/FR2848452B1/fr
Application filed filed Critical
Publication of JP2006514063A publication Critical patent/JP2006514063A/ja
Publication of JP2006514063A5 publication Critical patent/JP2006514063A5/ja
Abandoned legal-status Critical Current

Links

JP2004566119A 2002-12-12 2003-12-10 アルツハイマー病の予防および治療 Abandoned JP2006514063A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
PCT/FR2003/003654 WO2004062652A1 (fr) 2002-12-12 2003-12-10 Application et traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
JP2006514063A JP2006514063A (ja) 2006-04-27
JP2006514063A5 true JP2006514063A5 (enExample) 2007-01-25

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004566119A Abandoned JP2006514063A (ja) 2002-12-12 2003-12-10 アルツハイマー病の予防および治療

Country Status (22)

Country Link
EP (1) EP1572174A1 (enExample)
JP (1) JP2006514063A (enExample)
KR (1) KR20050084250A (enExample)
CN (1) CN1726016A (enExample)
AR (1) AR042354A1 (enExample)
AU (1) AU2003296802A1 (enExample)
BR (1) BR0317280A (enExample)
CA (1) CA2507945A1 (enExample)
CO (1) CO5700712A2 (enExample)
FR (1) FR2848452B1 (enExample)
HR (1) HRP20050534A2 (enExample)
MA (1) MA27500A1 (enExample)
MX (1) MXPA05005556A (enExample)
NO (1) NO20053341L (enExample)
NZ (1) NZ540496A (enExample)
PE (1) PE20040770A1 (enExample)
PL (1) PL377110A1 (enExample)
RS (1) RS20050420A (enExample)
RU (1) RU2005121909A (enExample)
TW (1) TW200503707A (enExample)
WO (1) WO2004062652A1 (enExample)
ZA (1) ZA200504656B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CN1918131B (zh) 2004-02-05 2011-05-04 前体生物药物股份公司 谷氨酰胺酰基环化酶抑制剂
CA2589102C (en) 2004-11-02 2013-08-13 Northwestern University Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
PL2157973T3 (pl) * 2007-05-22 2015-12-31 Otsuka Pharma Co Ltd Lek zawierający pochodną karbostyrylu i donepezil do leczenia choroby Alzheimera
AU2012328453B2 (en) * 2011-10-28 2017-05-04 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
ES2633766T3 (es) * 2011-10-28 2017-09-25 Lumena Pharmaceuticals Llc Inhibidores de reciclaje de ácido biliar para el tratamiento de enfermedades de hígado colestático pediátrico

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
AU668682B2 (en) * 1991-02-22 1996-05-16 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
EP0910351A1 (en) * 1996-06-27 1999-04-28 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
NZ505761A (en) * 1998-01-28 2003-08-29 Warner Lambert Co Method for treating alzheimer's disease using plasma-triglceride level-lowering agents or agents that interfer with cholesterol ester synthesis
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
WO2001056579A1 (en) * 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Similar Documents

Publication Publication Date Title
JP5576591B2 (ja) α,α,α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
JP2008526757A5 (enExample)
JP2006523216A5 (enExample)
JP2006182786A5 (enExample)
CA2528784A1 (en) Hexahydropyridoisoquinolines as dpp-iv inhibitors
CA2430692A1 (en) Geldanamycin derivative and use of same to treat cancer
MXPA01006474A (es) Derivados colquinol como agentes perjudiciales vasculares.
JP2012506872A5 (enExample)
EP1772142A3 (en) Organic compounds
JP2004516314A5 (enExample)
JP2003509349A5 (enExample)
JP2006503850A5 (enExample)
JP2004506740A5 (enExample)
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
JP2023540149A (ja) 抗ウイルス化合物の製剤
JP2009513713A5 (enExample)
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
JP2010505865A5 (enExample)
JP2006514063A5 (enExample)
JP2001520994A5 (enExample)
RU2004133387A (ru) Фармацевтический препарат с немедленным высвобождением
EP1857442A3 (en) Novel antimycobacterial compounds
RU2004131214A (ru) Способы лечения когнитивных расстройств
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
RU2006141647A (ru) Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний